Disease Landscape and Forecast Insights

The treatment of breast cancer is associated with strong commercial opportunity because of the disease’s high incidence, long treatment durations, and multiple lines of therapy. The CDK4/6…

Clarivate Epidemiology’s coverage of colorectal cancer comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence of…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key colorectal cancer patient populations, covering 171 countries and…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key diabetic retinopathy patient populations, covering 171 countries and…

Clarivate Epidemiology’s coverage of Diabetic Retinopathy (DR) comprises epidemiological estimates of key patient populations across 45 countries worldwide. We report both the diagnosed prevalence…

Clarivate Epidemiology’s coverage of diabetic retinopathy comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Obesity is a significant and growing public health concern in the G7 countries. The body of evidence highlighting the medical and economic impact of obesity on society is steadily increasing…

Clarivate Epidemiology’s coverage of allergic rhinitis (AR) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France,…

Pulmonary hypertension (PH) is a devastating disease with high levels of morbidity and mortality and no cure. Despite the rarity of the disease, the potential commercial opportunities for drugs…

The rising rates of antimicrobial resistance (AMR) have created an emergent need for development and discovery of antibiotics with activity against drug-resistant gram-negative pathogens (GNPs)…

The axial spondyloarthritis (AxSpA) therapy market includes biologics from two distinct drug classes: tumor necrosis factor-alpha (TNF-α) inhibitors (Amgen / Pfizer’s Enbrel, AbbVie’s Humira,…

The gastroesophageal cancer therapy market (including gastric, gastroesophageal junction, and esophageal cancer) is rapidly evolving and experiencing substantial growth, largely driven by the…